USDA grants a license for the first monoclonal antibody therapy to control canine atopic dermatitis


In New Jersey, Zoetis Inc. announced that the U.S. Department of Agriculture granted a license for CYTOPOINT, the first monoclonal antibody therapy approved to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs. CYTOPOINT targets and neutralizes interleukin-31, a key protein involved in triggering itch in dogs and provides fast, effective relief of itching – the hallmark sign of the allergic skin condition atopic dermatitis in dogs.

“CYTOPOINT results from our acquiring a deeper scientific understanding of the causes of allergic skin conditions in dogs at the molecular level and developing novel, targeted, effective treatments based on these new insights,” said Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis.

One injection every four to eight weeks helps to improve the long-term quality of life for dogs suffering from atopic dermatitis and is now available to all veterinarians in the United States.